Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

by Lindblad, O, Cordero, E, Puissant, A, Macaulay, L, Kabir, N N, Sun, J, Vallon-Christersson, J, Haraldsson, K, Borg, Å, Levander, F, Stegmaier, K, Pietras, K, Rönnstrand, L, Kazi, J U, Ramos, A., Hemann, Michael
Published 2017

EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma

by Abraham, B.J, Bikowitz, M.J, Bulyk, M.L, Conway, A.S, Dharia, N.V, Durbin, A.D, Easton, J., Li, D., Look, A.T, Mariani, L., Maxham, L., Morita, K., Mundada, M., Nance, S., Park, P.M.C, Patel, A.G, Perez-Atayde, A.R, Qi, J., Quinn, T.R, Robichaud, A.L, Schönbrunn, E., Shao, Y., Shendy, N.A.M, Sigua, L.H, Stegmaier, K., Wang, T., Wiest, O., Wimalasena, V.K, Zimmerman, M.W
Published 2022